Home / Business and Economy / AlzeCure Eyes $1B+ Payout from Eli Lilly Alzheimer's Pact
AlzeCure Eyes $1B+ Payout from Eli Lilly Alzheimer's Pact
9 Jun
Summary
- AlzeCure and Eli Lilly formed a collaboration for Alzheimer's treatment.
- The deal could be worth over $1 billion in total value.
- AlzeCure focuses on drug candidates for CNS diseases like Alzheimer's.
AlzeCure Pharma has announced a major collaboration and out-licensing agreement with Eli Lilly. This partnership focuses on an Alzheimer's disease treatment, with Eli Lilly securing the global rights.
The potential total value of this deal is substantial, projected to exceed $1 billion. This signifies a significant milestone for AlzeCure, a company dedicated to developing innovative drug candidates.
AlzeCure's research specifically targets central nervous system diseases. Their primary focus areas include the development of treatments for Alzheimer's disease and pain management. This agreement with Eli Lilly marks a key step in advancing their Alzheimer's therapeutic efforts.
